Stevanato Group (STVN) Aktievy
Stevanato Group S.p.A. är verksamt inom design, produktion och distribution av produkter och processer för att tillhandahålla lösningar för biopharma- och hälsovårdsindustrin i Europa, Mellanöstern, Afrika, Nordamerika, Sydamerika och Asien och Stillahavsområdet. Mer information
| Snöflinga Score | |
|---|---|
| Värdering | 4/6 |
| Framtida tillväxt | 2/6 |
| Tidigare resultat | 5/6 |
| Finansiell hälsa | 6/6 |
| Utdelningar | 0/6 |
Belöningar
Riskanalys
Inga risker upptäckta för STVN från våra riskkontroller.
STVN Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
LO
Lou_Basenese
Community ContributorUS$7.6FV • 75.3% undervärderad intrinsisk rabatt
5022.2%Revenue growth p.a.
3.7k
23
2
54
Stevanato Group S.p.A. Konkurrenter
Prishistorik och prestanda
| Historiska aktiekurser | |
|---|---|
| Aktuell aktiekurs | US$17.71 |
| 52 veckors högsta | US$28.00 |
| 52 veckors lägsta | US$12.89 |
| Beta | 0.62 |
| 1 månads förändring | 28.80% |
| 3 månaders förändring | 13.67% |
| 1 års förändring | -17.17% |
| 3 års förändring | -34.04% |
| 5 års förändring | n/a |
| Förändring sedan börsintroduktionen | -9.96% |
Senaste nyheter och uppdateringar
STVN: Core Biologics Shift Will Drive Future Earnings Power
Analysts have trimmed their Stevanato Group price targets by several dollars across the Street, now clustering in a $19 to $32 range, as they refresh models after Q4 results and factor in slightly lower long term margin, growth, and P/E assumptions, alongside shifting expectations for GLP-1 and core biologics revenue contributions. Analyst Commentary Recent research updates show analysts marking down their price targets but still drawing a clear line between near term noise and the longer term setup for Stevanato Group, especially around GLP-1 exposure and the broader biologics portfolio.
STVN: Biologics And GLP-1 Exposure Will Support Future Upside Potential
Analysts have trimmed the Stevanato Group fair value estimate from $18.09 to $17.50 after a series of reduced Street price targets, citing updated models post Q4 results, a higher discount rate, slightly softer revenue growth and margin assumptions, and a higher future P/E multiple that still reflects support for the core biologics and GLP-1 exposure. Analyst Commentary Recent Street research has largely centered on resetting expectations after Q4, with several bearish analysts trimming price targets while still recognizing the support from biologics and GLP-1 exposure.
STVN: Biologics Focus And On Body Delivery Collaboration Will Drive Future Cash Flows
Analyst price targets for Stevanato Group have been reduced across several firms, with cuts ranging from $5.50 to $8 per share as analysts factor in updated Q4 results, a shift in GLP-1 growth expectations, and a greater focus on the core biologics and engineering businesses. Analyst Commentary Recent Street research on Stevanato Group reflects a mix of reduced price targets and generally supportive views on the company’s execution in biologics, premium formats, and GLP-1 related revenue.STVN: Biologics Mix Shift And On Body Delivery Partnership Will Support Future Cash Flows
Analysts have trimmed their consolidated price target on Stevanato Group by $4.09 to $32.00. This reflects updated models after Q4 results, slightly lower fair value assumptions, modestly higher discount rates, and more measured expectations for revenue growth, profit margins, and future P/E, even as they continue to highlight strength in GLP-1 and broader biologics demand.Recent updates
STVN: Core Biologics Shift Will Drive Future Earnings Power
Analysts have trimmed their Stevanato Group price targets by several dollars across the Street, now clustering in a $19 to $32 range, as they refresh models after Q4 results and factor in slightly lower long term margin, growth, and P/E assumptions, alongside shifting expectations for GLP-1 and core biologics revenue contributions. Analyst Commentary Recent research updates show analysts marking down their price targets but still drawing a clear line between near term noise and the longer term setup for Stevanato Group, especially around GLP-1 exposure and the broader biologics portfolio.STVN: Biologics And GLP-1 Exposure Will Support Future Upside Potential
Analysts have trimmed the Stevanato Group fair value estimate from $18.09 to $17.50 after a series of reduced Street price targets, citing updated models post Q4 results, a higher discount rate, slightly softer revenue growth and margin assumptions, and a higher future P/E multiple that still reflects support for the core biologics and GLP-1 exposure. Analyst Commentary Recent Street research has largely centered on resetting expectations after Q4, with several bearish analysts trimming price targets while still recognizing the support from biologics and GLP-1 exposure.STVN: Biologics Focus And On Body Delivery Collaboration Will Drive Future Cash Flows
Analyst price targets for Stevanato Group have been reduced across several firms, with cuts ranging from $5.50 to $8 per share as analysts factor in updated Q4 results, a shift in GLP-1 growth expectations, and a greater focus on the core biologics and engineering businesses. Analyst Commentary Recent Street research on Stevanato Group reflects a mix of reduced price targets and generally supportive views on the company’s execution in biologics, premium formats, and GLP-1 related revenue.STVN: Biologics Mix Shift And On Body Delivery Partnership Will Support Future Cash Flows
Analysts have trimmed their consolidated price target on Stevanato Group by $4.09 to $32.00. This reflects updated models after Q4 results, slightly lower fair value assumptions, modestly higher discount rates, and more measured expectations for revenue growth, profit margins, and future P/E, even as they continue to highlight strength in GLP-1 and broader biologics demand.STVN: Large-Volume Self-Administration Partnership Will Support Future Upside Potential
Analysts have trimmed their 12 month price target on Stevanato Group by about $4.90 per share to reflect updated assumptions around fair value, discount rate, revenue growth, profit margins, and future P/E multiples, citing recent Street research calls that include Jefferies cutting its target by $5.50. Analyst Commentary Bearish analysts are signaling a more cautious stance on Stevanato Group, reflected in reduced 12 month price targets that factor in updated views on fair value, discount rates, revenue growth, profit margins, and future P/E multiples.STVN: Large Volume On-Body Delivery Partnership Will Support Stronger Future Cash Flows
Analysts have nudged their fair value estimate for Stevanato Group slightly higher to US$36.09, citing small adjustments to discount rate assumptions, revenue growth outlook, profit margin expectations, and a refined future P/E framework. What's in the News Datwyler, LTS Device Technologies and Stevanato Group entered a collaboration focused on large volume subcutaneous drug delivery using on-body administration for larger dose volumes (Key Developments).Why We're Not Concerned Yet About Stevanato Group S.p.A.'s (NYSE:STVN) 27% Share Price Plunge
Feb 04
STVN: Large Volume Drug Delivery Collaboration Will Support Stronger Future Cash Flows
Analysts have nudged their price target for Stevanato Group slightly higher to $36.08 from $36.05, citing updated assumptions for revenue growth, profit margins, and future P/E that modestly adjust their long term valuation. What's in the News Datwyler, LTS Device Technologies and Stevanato Group announced a collaboration focused on large volume subcutaneous drug delivery, targeting more convenient on body administration of larger doses for patients, with a joint platform to be presented at Pharmapack in Paris on January 21 to 22, 2026 (Key Developments).STVN: Expanded Drug Delivery Capacity Will Support Stronger Future Cash Flows
Analysts now estimate Stevanato Group's fair value price target at approximately US$36.05, a very small adjustment from about US$36.08. This reflects updated views that combine slightly higher revenue growth expectations with modestly lower profit margin assumptions and a marginally higher future P/E outlook.Are Stevanato Group S.p.A. (NYSE:STVN) Investors Paying Above The Intrinsic Value?
Jan 06Stevanato: Structural Growth Intact, Buy Confirmed
Jan 03STVN: Expanded Drug Delivery Capacity Will Support Stronger Future Cash Flows
Analysts have nudged their price target on Stevanato Group slightly higher to approximately $36.08 per share from about $36.05, citing modestly stronger expectations for revenue growth and profit margins that more than offset a small anticipated decline in the company’s future price to earnings multiple. What's in the News Maintained 2025 revenue guidance, expecting between €1.160 billion and €1.190 billion, signaling confidence in demand and operational execution (Corporate Guidance) Announced a significant expansion of drug delivery system manufacturing capacity in Bad Oeynhausen, Germany, adding over 2,500 square meters of advanced production space to support global pharma and biotech customers (Business Expansions) Invested multi millions in an ISO 8 cleanroom environment equipped for injection molding and automated assembly, aimed at strengthening resilient, Europe based supply chains for partners (Business Expansions) Enhanced the Bad Oeynhausen site to scale production of key devices such as the Aidaptus autoinjector and Alina pen injector platforms, reinforcing the company’s role in patient centric combination products (Business Expansions) Valuation Changes Fair Value Estimate has risen slightly to approximately $36.08 per share from about $36.05.STVN: Expanded Drug Delivery Capacity Will Support Stronger Future Profit Margins
Analysts have modestly trimmed their price target on Stevanato Group to approximately $36.05 from about $36.07, reflecting slightly higher perceived risk via a raised discount rate, which is only partly offset by improved profit margin expectations and a marginally lower forecast valuation multiple. What's in the News Maintained 2025 revenue guidance, with expected revenue in the range of €1.160 billion to €1.190 billion (Corporate guidance) Announced a significant expansion of drug delivery system manufacturing capacity at its Bad Oeynhausen, Germany facility, adding over 2,500 square meters of advanced production space (Business expansion) Invested multiple millions in a new ISO 8 cleanroom, injection molding, and automated assembly operations to support global pharma and biotech partners with resilient European supply chains (Business expansion) Strengthened production capabilities for key platforms, including the Aidaptus autoinjector and Alina pen injector, enhancing its role in patient centric combination products (Business expansion) Valuation Changes Fair Value Estimate: edged down slightly to approximately €36.05 from about €36.07 per share, reflecting a marginally lower intrinsic valuation.STVN: German Facility Expansion Will Drive Stronger Supply Chain Integration
Analysts have slightly lowered their price target for Stevanato Group, adjusting the fair value from $28.80 to $28.78 based on minor updates to growth and profitability expectations. What's in the News Stevanato Group S.p.A. maintained its revenue guidance for 2025, expecting revenues in the range of €1.160 billion to €1.190 billion (Key Developments).STVN: Expansion Of German Manufacturing Facility Will Fuel Future Upside
Narrative Update on Stevanato Group Price Target Analysts have raised their price target for Stevanato Group slightly, increasing it from $28.62 to $28.80. This change is attributed to modest improvements in projected revenue growth and profit margins, despite a higher discount rate.Investors Interested In Stevanato Group S.p.A.'s (NYSE:STVN) Earnings
Sep 22Here's What Analysts Are Forecasting For Stevanato Group S.p.A. (NYSE:STVN) After Its Second-Quarter Results
Aug 08Stevanato Group (NYSE:STVN) Takes On Some Risk With Its Use Of Debt
Jun 23A Look At The Intrinsic Value Of Stevanato Group S.p.A. (NYSE:STVN)
May 19Shareholders Should Be Pleased With Stevanato Group S.p.A.'s (NYSE:STVN) Price
Mar 26Stevanato: Ramping Syringe Demand, Buy Confirmed
Mar 09Is Stevanato Group (NYSE:STVN) A Risky Investment?
Feb 27Calculating The Fair Value Of Stevanato Group S.p.A. (NYSE:STVN)
Feb 01Stevanato Group S.p.A. (NYSE:STVN) Not Lagging Market On Growth Or Pricing
Dec 09
Engineering Optimization And Capacity Expansion To Unlock Growth Opportunities
Optimizing the Engineering segment and strategic shifts towards ready-to-use systems are expected to drive cost savings, improve margins, and boost productivity.Stevanato: Supportive Biopharmaceutical And Diagnostic Segment And Destocking Improvement
Nov 13Stevanato Group's (NYSE:STVN) Anemic Earnings Might Be Worse Than You Think
Nov 12Stevanato Group S.p.A. Just Missed Earnings - But Analysts Have Updated Their Models
Nov 08We Think Stevanato Group (NYSE:STVN) Is Taking Some Risk With Its Debt
Oct 23Is Stevanato Group S.p.A. (NYSE:STVN) Worth US$19.3 Based On Its Intrinsic Value?
Aug 21Stevanato Group S.p.A. (NYSE:STVN) Looks Just Right With A 28% Price Jump
Jul 25Does Stevanato Group (NYSE:STVN) Have A Healthy Balance Sheet?
Jul 23Stevanato: Destock Pressures, Long-Term Upside
May 29Stevanato Group S.p.A. Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now
May 12Stevanato Group S.p.A.'s (NYSE:STVN) Share Price Matching Investor Opinion
May 07Stevanato Group's (NYSE:STVN) Solid Earnings May Rest On Weak Foundations
Mar 15Stevanato: Destocking And Valuation Risk (Rating Downgrade)
Mar 12Is Stevanato Group S.p.A. (NYSE:STVN) Expensive For A Reason? A Look At Its Intrinsic Value
Feb 09Aktieägarnas avkastning
| STVN | US Life Sciences | US Marknad | |
|---|---|---|---|
| 7D | 9.5% | -0.3% | 0.8% |
| 1Y | -17.2% | 2.2% | 27.7% |
Avkastning vs industri: STVN presterade sämre än US Life Sciences branschen som gav 2.2 % under det senaste året.
Avkastning vs Marknaden: STVN presterade sämre än US marknaden som gav 27.7 % under det senaste året.
Prisvolatilitet
| STVN volatility | |
|---|---|
| STVN Average Weekly Movement | 8.7% |
| Life Sciences Industry Average Movement | 8.1% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.2% |
| 10% least volatile stocks in US Market | 3.3% |
Stabil aktiekurs: STVN har inte haft någon betydande prisvolatilitet under de senaste 3 månaderna jämfört med marknaden för US.
Volatilitet över tid: STVN s veckovolatilitet ( 9% ) har varit stabil under det senaste året.
Om företaget
| Grundad | Anställda | VD OCH KONCERNCHEF | Webbplats |
|---|---|---|---|
| 1949 | 6,010 | Franco Stevanato | www.stevanatogroup.com |
Stevanato Group S.p.A. är verksamt inom design, produktion och distribution av produkter och processer för att tillhandahålla lösningar för biopharma- och hälsovårdsindustrin i Europa, Mellanöstern, Afrika, Nordamerika, Sydamerika och Asien och Stillahavsområdet. Verksamheten bedrivs genom två segment, Biopharmaceutical and Diagnostic Solutions och Engineering. Företaget erbjuder lösningar för läkemedelsbehållare, inklusive förfyllningsbara sprutor, patroner, vialer och ampuller; lösningar för in vitro-diagnostik; system för läkemedelstillförsel, inklusive penninjektorer, autoinjektorer och bärbara injektorer; förbrukningsvaror för diagnostiska laboratorier; analytiska och regulatoriska stödtjänster; medicintekniska produkter; maskiner för visuell inspektion av läkemedel; monterings- och förpackningsmaskiner; maskiner för glasbearbetning; samt eftermarknadstjänster, såsom linjeoptimering och linjekonverteringar, utbildning, logistik, reservdelar och underhållstjänster.
Stevanato Group S.p.A. Sammanfattning av grunderna
| STVN grundläggande statistik | |
|---|---|
| Börsvärde | US$4.64b |
| Vinst(TTM) | US$163.88m |
| Intäkter(TTM) | US$1.39b |
29.5x
P/E-förhållande3.5x
P/S-förhållandeÄr STVN övervärderat?
Se Verkligt värde och värderingsanalysResultat & intäkter
| STVN resultaträkning (TTM) | |
|---|---|
| Intäkter | €1.19b |
| Kostnad för intäkter | €840.09m |
| Bruttovinst | €346.20m |
| Övriga kostnader | €206.36m |
| Intäkter | €139.84m |
Senast redovisade vinst
Dec 31, 2025
Nästa vinstdatum
May 07, 2026
| Vinst per aktie (EPS) | 0.51 |
| Bruttomarginal | 29.18% |
| Nettovinstmarginal | 11.79% |
| Skuld/egenkapitalförhållande | 30.7% |
Hur har STVN utvecklats på lång sikt?
Se historisk utveckling och jämförelseUtdelningar
0.4%
Aktuell utdelningsavkastning10%
UtbetalningskvotFöretagsanalys och finansiella data Status
| Uppgifter | Senast uppdaterad (UTC-tid) |
|---|---|
| Analys av företag | 2026/05/01 19:32 |
| Aktiekurs vid dagens slut | 2026/05/01 00:00 |
| Intäkter | 2025/12/31 |
| Årlig intjäning | 2025/12/31 |
Datakällor
Den data som används i vår företagsanalys kommer från S&P Global Market Intelligence LLC. Följande data används i vår analysmodell för att generera denna rapport. Data är normaliserade vilket kan medföra en fördröjning från det att källan är tillgänglig.
| Paket | Uppgifter | Tidsram | Exempel US-källa |
|---|---|---|---|
| Företagets finansiella ställning | 10 år |
| |
| Analytikernas konsensusuppskattningar | +3 år |
|
|
| Marknadspriser | 30 år |
| |
| Ägarskap | 10 år |
| |
| Förvaltning | 10 år |
| |
| Viktiga utvecklingstendenser | 10 år |
|
* Exempel för amerikanska värdepapper, för icke-amerikanska värdepapper används motsvarande regelverk och källor.
Om inget annat anges är all finansiell data baserad på en årsperiod men uppdateras kvartalsvis. Detta kallas data för efterföljande tolv månader (TTM) eller senaste tolv månader (LTM). Lär dig mer om detta.
Analysmodell och snöflinga
Detaljer om analysmodellen som användes för att skapa den här rapporten finns på vår Github-sida, vi har också guider om hur du använder våra rapporter och tutorials på Youtube.
Lär dig mer om det team i världsklass som utformade och byggde analysmodellen Simply Wall St.
Industri- och sektormått
Våra bransch- och sektionsmått beräknas var sjätte timme av Simply Wall St, detaljer om vår process finns tillgängliga på Github.
Källor för analytiker
Stevanato Group S.p.A. bevakas av 17 analytiker. 10 av dessa analytiker lämnade de uppskattningar av intäkter eller resultat som användes som indata till vår rapport. Analytikernas inskickade estimat uppdateras löpande under dagen.
| Analytiker | Institution |
|---|---|
| Hugo Solvet | BNP Paribas |
| Curtis Moiles | BNP Paribas |
| Michael Ryskin | BofA Global Research |